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Abstract  A subset of cancer survivors experience cognitive deficits that can last for many years after the 
completion of chemotherapy. The etiology of this problem is largely unknown, so the present study aimed to assess 
cognitive functioning in childhood patients with cancer and to investigate the proposed disposing factors including 
variables related to disease, treatment, and some socio-demographic characteristics. In a case control study parents 
of 67 cancer patients aged 8-12 years, completed the parent proxy report of PedsQL™ 3.0 Cognitive Functioning 
Scale (Arabic versions), as well as a separate sheet for socio-demographic data. Control group consisted of 37 
healthy subjects from the same age group were subjected to the same methodology for comparison. All patients 
under the study have successfully accomplished their treatment protocol and were in complete remission during the 
evaluation. Hematological malignancies represented 70.1% of the patients sample, with the highest proportion for 
ALL (52.2%). Brain tumors represented 40% of the solid malignancies (29.9% of the study patients). Cognitive 
functioning score was significantly lower in the solid group (69.6±37.3) compared to the hematologic group 
(85.1±22.2) (t = 2.1, p =0.038). Cognitive functioning score was also lower in solid group versus control subjects (p 
=0.047), while it showed no significant difference between hematological malignancies and control group. Older age 
at diagnosis, urban residence, illiterate mothers, higher duration of treatment as well as long duration of hospital 
admission were associated with a lower cognitive score in the solid tumors group compared to hematological group. 
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1. Introduction 
Pediatric cancer cases that occur in developing 
countries contributes for more than 85% of the whole 
childhood cancer population and are expected to exceed 
90% in the next two decades. [1] Worldwide, malignancies 
of the hematopoietic system are the largest subgroup of 
childhood cancers, accounting for 30% to 60% of all 
tumors. They are followed by tumors of the brain and 
nervous system (10% to 20%), bone (3% to10%) and liver 
(1% to 3%) [2].  
Generally speaking, unprecedented changes in 
diagnostic techniques, treatment methods and supportive 
care for childhood malignancies have occurred during the 
last decades. Consequently, management has improved 
and the mortality rates have decreased [1]. Higher survival 
rates in the different cancers have resulted in heightened 
focus on improving quality of life of survivors and 
reducing treatment-related late effects, including cognitive 
deficits [3]. 
Recent studies have reported difficulties in the abilities 
of cancer patients to remember, think, and concentrate [4]. 
This could be attributed both to the disease as well as 
treatment [5]. Moreover, little is still known about the 
effects of chemotherapy on cognitive functions [6]. Hence, 
cognitive competency as one of the crucial lifestyle factors 
merits more attention in childhood cancer patients, with 
serious investigation of the degree to which cognitive 
performance could be affected by the different treatment 
regiments as well as the expected role of the type and 
prognosis of the disease itself [7]. 
As for developing countries in particular, they suffer 
from geographic inequality in cancer treatment compared 
to those in countries with advanced health care systems 
[8,9]. Moreover, Incidence rates, pathology, and clinical 
characteristics of various cancers seem different in 
developing and developed countries mainly due to 
different environments, life styles, dietary habits, and 
hygienic conditions. [1] According to experts, it is high 
recommended to broaden research which involves cases in 
developing countries putting in mind that progress in 
pediatric cancer treatment in Western countries has been 
attributed to a great extent to the serious, successive and 
continuous cancer research [10].  
Consequently, the present study aimed to assess 
cognitive functioning in a pilot sample of childhood 
20 Journal of Cancer Research and Treatment  
 
patients with cancer in Egypt. And to investigate the 
predisposing factors to cognitive impairments including 
variables related to disease, treatment, and some socio-
demographic characteristics. 
2. Patients and Methods 
2.1. Patients 
A convenient sample of 67 pediatric cancer patients -
aged from 8 to 12 years- with established diagnosis at the 
pediatric Oncology Department of the National Cancer 
Institute of Egypt were included onto the present work. 
The study was explorative and recruited patients of either 
hematological or solid malignancies at different phases of 
their treatment. Parents of every included patient were 
asked to complete the PedsQL™ 3.0 Cognitive 
Functioning Scale [11] (Arabic versions), as well as a 
separate sheet in which maternal education, residence 
(urban or rural), family size, age at diagnosis and gender 
were included. Control group consisted of 37 healthy 
subjects from the same age group and were subjected to 
the same methodology. 
2.1.1. Instrument 
The parent proxy-report for children aged 8-12 years of 
the PedsQL™ 3.0 Cognitive Functioning Scale is a 6 item 
scale to assess different facets of cognitive functioning. A 
5 point likert scale ranging from 0 for "never a problem" 
till 4 for "almost always a problem" was used to rank each 
item of the scale. A corresponding score from 0 to 100 is 
then calculated, where 0 represents the worst state of 
cognitive functioning and 100 represents the best one. 
Finally, the average of the scores for all items represents 
the total score of cognitive functioning. 
2.1.2. Linguistic Translation 
Items of the PedsQL™ 3.0 Cognitive Functioning Scale 
were translated into Arabic (native language of the study 
sample) using the PedsQL™ Measurement Model 
Translation Methodology. Linguistic validation process 
included forward translation from the source language 
(English) to the target language (Arabic), backward 
translation to the source language, and cognitive 
debriefing according to PedsQL™ Cognitive Interviewing 
MethodologySM [12,13]. A report for every step 
throughout the whole process was sent to Mapi research 
Institute in Lyon, France, on behalf of Dr. James W. Varni, 
the copyright owner of the questionnaire for approval that 
was successfully issued.  
2.2. Measures 
2.2.1. Intensity of Treatment 
Intensity of treatment received by patients of the study 
sample was rated on a 3-point scale, with 1 = low: surgery 
only or six months chemotherapy only or both, with a 
favorable prognosis; 2 = medium: treatment longer than 6 
months according to the treatment protocol, with an 
intermediate prognosis; 3 = high: treatment according to 
intensive protocols, bone marrow transplantation, with 
unfavorable prognosis [14,15]. 
Phase of treatment; patient actively receiving therapy at 
any phase of the treatment protocol were defined as on-
treatment group. Whereas, the follow-up group indicated 
patients who ended their treatment and were scheduled for 
timed interval follow up. 
Therapy duration; short if ≤6 month, between 6 month 
and 1 year was medium, and ≥1 year defined as long 
duration of therapy.  
Length of hospital admission; had 3 levels: low for 
admission periods within one third of the total duration of 
therapy, medium if admission period was more than one 
third and less than 2 thirds of the total duration, and high 
if it exceeded 2 thirds the total treatment duration.  
3. Statistical Analysis 
Score of the Cognitive Functioning Scale for each 
participant was calculated according to the guidelines of 
the PedsQL™ Cognitive Functioning Scale developer. 
Descriptive statistics were expressed as mean, median, 
and standard deviation. Data analysis was performed using 
the student t-test for the comparison between two groups, 
one way ANOVA was used for multiple group 
comparison, and a value of p < 0.05 was considered 
significant. Analyses were conducted using SPSS (SPSS 
Inc., Chicago, IL, with SPSS version 18). 
4. Results 
In order to obtain discriminative values with apparent 
significance the study sample of childhood cancer patients 
is divided into two groups according to the type of disease; 
group 1 for patients with hematologic diseases and group 
2 for patients with solid tumors. Group 3 is represented by 
normal controls of age matched children. Demographic 
information and other descriptive data for the study groups 
are provided in Table 1. Hematologic cancers are 
represented by ALL (35/47), non Hodgkin lymphoma 
(5/47) Hodgkin lymphoma (4/47) and AML (1/47). For 
the solid tumors, 25% have brain tumors, 25% suffer from 
Ewings sarcoma and 15% are diagnosed for MB. Study 
patients were 33 males and 14 females in the hematologic 
group with a median age of 7.5 years at diagnosis and 5.02 
as mean value for family size. While in the solid tumor 
group there were 10 males and 10 females with a median 
age of 7.9 years at diagnosis and 5.8 as mean value for 
family size. There was no difference between the groups 
with regard to the age at diagnosis (t =-0.5, p =0.6) and 
family size (F=2.1, p=0.12). The urban/rural distribution 
in the three groups is as follows: 54%/46%, 57%/43% and 
68%/32% for the hematologic, solid tumors and control 
groups, respectively. Some maternal education is shown 
for 59% in the hematologic group, 50% in the solid group 
and 90% in the control group. The on-treatment and 
follow-up phase of treatment show very close percentages 
in both hematologic (53% and 47%) and solid tumor 
groups (55% and 45%). High therapy duration of 1 year or 
above at time of evaluation prevails in both hematologic 
and solid tumor groups and represents 51% and 50% of 
study sample in the 2 groups, respectively. As for the 
Cognitive Functioning Scale mean score, it showed to be 
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85.1, 69.6 and 83.2 for the hematologic, solid tumor and control groups, respectively. 
Table 1. Socio demographic, cancer and treatment variables in patients and controls 
 Hematologic malignancies Solid tumors Control group 













ALL 35(74.4%) -- -- 
NHL 5(10.6%) -- -- 
HDL 4(8.5%) -- -- 
Others 3(6.5%) -- -- 
Brain tumours --- 8 (40%) -- 
E S --- 5 (25%) -- 
OS --- 2 (10%) -- 
N.B --- 2 (10%) -- 
Others  3 (15%)  
Sex (n %) 
male 33 (70%) 10 (50%) 16 (43%) 
Female 14 (30%) 10 (50%) 21 (57%) 
Residence (n %) 
urban 25 (54%) 9 (47%) 25 (68%) 
rural 21 (46%) 10 (53%) 12 (32%) 
Family size (Mean±SD) 5.02±1.01 5.8±1.7 5.13±1.8 
Age at diagnosis (Mean±SD) 7.51±2.97 7.9±2.6 - 
Maternal education 
 
Yes 27(59%) 10(50%) 28(90%) 




high 21(45%) 6(30%)  
Medium 14(30%) 6(30%) --- 
Low 11(23%) 7(35%)  
Stage of treatment 
 
on treat. 25(53%)  11(55%)  
 9(45%) --- Follow up 22(47%) 
Intensity of therapy 
 
 
high 11(23%) 10(50%)  
Medium 30(64%) 10(50%) --- 




high 24(51%) 10(50%)  
Medium 16(34%) 5(25%) --- 
low 7(15%) 5(25%)  
Cognitive functioning 85.1±22.2 69.6±37.3 83.2±13.04 
ALL= Acute Lymphoblastic Leukemia; NHL=Non Hodgkin Lymphoma; HD=Hodgkin Lymphoma; ES=Ewing's sarcoma; OS=Osteosarcoma; 
NB=Neuroblastoma. 
As shown in (Figure 1) the comparison between the 
three studied groups (hematological malignancies, solid 
tumors and control group) as regard their cognitive 
functioning score revealed that solid tumor group had the 
lowest score (p value = 0.04). Moreover, statistically 
significant difference was shown upon comparing the 
hematologic group and solid tumor group (t = 2.1, p 
=0.038), and again between solid tumor group and control 
subjects (p =0.047) revealing in both cases declined 
cognitive functioning within patients with solid tumors. 
 
Figure 1. Mean cognitive functioning score of the studied groups, showing a lower score for the solid tumour group than the other two groups, p value 
(ANOVA) = 0.04 
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Table 2 shows the impact of some socio-demographic 
variables on cognitive functioning score. To search the 
effect of the age at diagnosis on cognitive functioning, 
cases were divided into two subgroups: (i) the first group: 
children younger than or equal to 5 years and (ii) the 
second group: children older than 5 years at the time of 
diagnosis. As shown by the results the second group 
(older than five years) was associated with lower cognitive 
functioning score (69.3) in the solid group compared to 
the score (86.7) for group with hematological 
malignancies at the same age category. Urban residence 
also significantly affected the cognitive functioning score 
(51.84) of the solid group which showed to be lower than 
scores of the other two groups; the hematological 
malignancies and normal control (83.98 and 85.3, 
respectively) with a level of significance = 0.001. 
Negative maternal education was another factor that 
negatively affected the scoring of the solid group (67.08) 
in comparison to hematologic group (89.9) with p value of 
0.03 using student t test (not mentioned in the table). To 
look for the effect of sex, cognitive functioning score for 
males and females were analyzed separately, but no 
statistically significant differences were found between the 
groups. Also, there was no significant difference between 
the groups in their cognitive functioning score in relation 
to their family size. 
Table 2. Effect of some studied socio demographic variables on cognitive functioning score of the studied groups 
 
Hematologic Solid control p-value 
Mean±SD(n)  
Age at diagnosis 0-5 81.23 ±22.57 (14) 69.43 ± 29.25 (3)  0.4 
 >5 86.7 ± 22.2 (33) 69.6 ± 39.32 (17) ---- 0.05* 
Sex male 83.32 ± 22.64 (33) 71.23 ± 39.79 (10) 84.6±10.4(16) 0.3 
 Female 89.27 ± 21.49(14) 67.92 ± 36.74 (10) 82.1±14.9(21) 0.09 
Residence urban 83.98±21.51(25) 51.84±39.25(9) 85.3±14.5(25) 0.001** 
 rural 85.9±23.96(21) 82.49±31.1(10) 78.8±8.00(12) 0.7 
Family size 0-4 83.6 ± 25.6(12) 60.00 ± 54.7 (5) 86.97±16.7(8) 0.2 
 >4 85.58 ± 21.33 (35) 72.76 ± 31.44 (15) 81.1±12.4(23) 0.3 
Maternal education Yes 81.77±24.52(27) 72.07± 40.06(19) 81.7±13.8(28) 0.8 
 No 89.9±18.8(19) 67.08± 36.3(10) 91.6±8.4(3) 0.07 
* Significant t- test p<0.05  ** Highly significant one-way (ANOVA) p<0.01. 
Table 3 shows the impact of some treatment variables 
on cognitive functions of cancer childhood patients as 
compared between hematologic and solid cancer groups. 
High therapy duration as well as long duration of hospital 
admission were associated with a lower cognitive 
functioning score (56.66 and 51.38, respectively) in the 
solid tumors group than the scores (83.83 and 86.1, 
respectively) in the hematological group (p<0.05), while 
different intensities of therapy and the stage of treatment 
although negatively affected scores in patients with solid 
tumors compared to those with hematological 
malignancies, yet such differences were not significant. 
Table 3. The impact of cancer treatment variables on cognitive functioning score 
 Hematologic Solid p-value 
 Mean±SD (n)  
Intensity of therapy high 82.56 ± 23.63 (11) 64.16 ± 38.3 (10)  
 Medium 83.18 ±23.31 (30) 74.99 ± 37.52 (10) 0.2 
 low 99.30 ± 1.71 (6) ------ 0.4 
Therapy duration high 83.83 ± 20.65 (24) 56.66 ± 39.67(10) 0.01** 
 Medium 83.5 ±27.58 (16) 95.00 ±11.18 (5) 0.38 
 low 92.84 ± 13.14 (7) 69.98 ±41.49 (5) 0.19 
Hospital admission high 86.1 ±23.84(21) 51.38± 45.46(6) 0.017* 
 Medium 83.32 ± 23.58(14) 83.32 ± 12.08(6) 1.00 
 low 87.11 ± 19.24(11) 69.04 ± 43.49 (7) 0.24 
Stage of treatment on treat. 87.82 ±22.41 (25) 75.74 ± 31.7(11) 0.19 
 Follow up 81.99 ± 22.14 (22) 62.03 ± 43.96 (9) 0.1 
* Significant t- test p<0.05 **highly significant- test p<0.01. 
5. Discussion 
Deteriorated cognitive functioning in children with 
cancer could be attributed either to cancer per se and/or 
cancer treatments -including chemotherapy- as described 
by Vardy et al [16]. The current study compared -parent-
reported- cognitive functioning between normal children 
and two different groups of childhood malignancies; solid 
tumors and hematological cancers. Patients with solid 
tumors (40% brain tumors) showed significantly lower 
cognitive functioning score compared to those with 
hematologic malignancies and the healthy control which 
may suggest a prominent role for solid tumors -in 
particular- in cognitive dysfunction reported in childhood 
cancer patients. This shows to be consistent with research 
results recording early cognitive impairment in children 
with brain tumors sometimes even prior to 
radiotherapy/chemotherapy treatment [17]. Earlier studies 
which reported cognitive impairment in 15%–50% of 
adult solid tumor survivors could also suggest some kind 
of serious role of the type of disease (solid tumors) in 
affecting cognitive state of cancer survivors [18,19,20]. 
On the contrary, group representing hematological 
cancers in the current study -in which ALL constituted the 
largest proportion (74.4 %) of its composition- showed 
matched results to normal control in the cognitive 
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functioning scale which means that neither the disease nor 
its treatment affected cognition in the represented sample. 
This goes in agreement with some studies on ALL 
childhood patients [21]. 
As for chemotherapy in specific and its effect on 
cognitive function of childhood cancer patients, although 
several studies [18,19,20,22] have found evidence 
supporting the influence of chemotherapy on cognitive 
functioning, yet negative studies have also been reported. 
[23,24,25,26,27] This discrepancy may be due to one or 
more of factors reported by Vardy et al. [16] which 
included the different chemotherapy regimens 
administered, variations in normative data and reference 
groups, statistical cut-offs used to define cognitive 
impairment and others. Moreover, Becham (1988, 1989) 
reported that cognitive dysfunction due to chemotherapy 
may not appear immediately after treatment but needs at 
least from 2 to 3 years after treatment cessation which is 
not the case in the study sample [28,29]. 
In addition to the effect of the type of cancer and the 
role of chemotherapy, number of variables investigated in 
our study showed to contribute significantly to the 
deterioration of cognitive functioning in pediatric patients 
with solid tumors compared to patients with hematological 
malignancies and/or normal control. The indicated 
variables included treatment related variables like long 
therapy duration and excessive hospital admission; that 
agrees with Whittington (2007), who reported that, the 
time since treatment is an important indicator of risk for 
cognitive problems [30] together with length of hospital 
admission which is known to affect quality of life of 
cancer patients in general.  
In consistence with literature [31], results of the current 
study also showed some host factors to influence the 
neurocognitive outcomes. Such factors included older age 
at diagnosis, urban residence and illiterate mothers which 
were associated with a lower cognitive functioning score 
in the solid tumors group compared to hematological 
group. Young age at diagnosis –generally- was 
demonstrated to be a risk factor for cognitive dysfunction 
in children cancers over time [30] with reported higher 
risk for cognitive sequelae in patients younger than 6 to 8 
years [32] as it is crucial time for cognitive development. 
In the present study all of our patients belonged to the 
high risk group with respect to age at diagnosis, yet our 
results showed patients with solid tumors to have their 
cognitive function much more deteriorated than the other 
group with hematological diseases. Such a decrease was 
significant in the group with age older than 5 years at 
diagnosis and could be explained –in our consideration- 
by the suggested frequent school absence. Non significant 
decrease in the group with age less than 5 years at 
diagnosis on the other hand may be due to the small 
number of patients and the subsequent large value of SD.  
Negative maternal education in our study also showed 
to be significantly associated with worse cognitive 
functioning score in patients with solid malignancies in 
accordance with other studies [33]. Children with solid 
cancers living in rural regions did not show significant 
difference in the cognitive functioning scale score 
compared to patients with hematological diseases. On the 
other hand urban residence showed to affect cognitive 
functioning negatively in patients with solid tumors. 
According to Wells [31] window views onto green 
vegetation, rather than bare dirt or pavement were 
associated with increased cognitive function in low-
income children generally and this could explain why 
children with solid tumors in urban residence showed 
significantly more deteriorated cognitive functioning 
scores than those in rural areas. In contrast to several 
studies which revealed that girls perform more poorly than 
boys in cognitive tests [21, 35] negligible effect of sex was 
found in the present work.  
6. Conclusion 
In conclusion, there is a crucial need of cognitive 
function testing at the time of cancer diagnosis as a 
baseline as well as the different stages of disease and 
treatment to clarify the specific role of the tumor type, 
surgery, type of treatment and medical procedures in the 
possible cognitive decline of children with different types 
of cancers. After the current work, we can suggest that the 
parent-proxy Ped'sQL Cognitive functioning Scale could 
be a potential screening measure for cognitive function in 
childhood cancer patients as it was able to discriminate 
between diseased and healthy children as well as between 
patients with solid and hematological diseases with 
respect to cognitive functioning. More detailed 
neuropsychological tests are needed for specific 
information about the nature and severity of cognitive 
dysfunction at different loci throughout the length of the 
treatment period and even for long term survivors as a 
second step to provide a better view for specific issues 
related to cognitive dysfunction in childhood cancer 
patients. Besides, studies on big samples are also 
recommended to clarify the role of predisposing variables. 
Furthermore, development of interventions that address 
cognitive late effects is imperative, intervention studies 
can be more efficiently designed to target the underlying 
mechanisms to try and prevent cognitive impairment from 
occurring and to treat it once it has occurred.[16] Last but 
not least, developing countries represent a highly fertile 
medium for health research, there are very much low 
available data describing the health conditions of 
childhood cancer patients even on the level of preliminary 
screening studies. 
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